Sleep & Recovery Peptide Stack 2026: Epithalon + DSIP + Ipamorelin + Selank Research Protocol

# Sleep & Recovery Peptide Stack 2026: Epithalon + DSIP + Ipamorelin + Selank Research Protocol

> For research purposes only. Not for human use. All compounds described in this article are research peptides under scientific investigation and are not approved by the FDA or any other regulatory agency for human consumption. This content is intended for educational and research purposes only and does not constitute medical advice.

Sleep is not simply rest — it is the period during which the body performs its most critical repair and regulatory functions. Growth hormone secretion peaks during slow-wave sleep, immune memory consolidates during REM cycles, and the brain clears metabolic waste through the glymphatic system. Disrupted sleep architecture accelerates biological aging, impairs cognitive performance, and undermines physical recovery.

Peptide researchers have long been interested in compounds that interact with the neuroendocrine systems governing sleep. Several research peptides show distinct mechanisms for modulating sleep quality, circadian rhythm, and overnight hormonal dynamics. This guide examines four compounds — Epithalon (Epitalon), DSIP (Delta Sleep-Inducing Peptide), Ipamorelin, and Selank — and explores how researchers are studying them both individually and in combination.

---

Understanding Sleep Architecture: Why Researchers Study Peptide Interventions

Normal sleep consists of alternating NREM (non-rapid eye movement) and REM (rapid eye movement) cycles, each approximately 90 minutes in duration. NREM sleep — particularly slow-wave sleep (SWS or Stage 3) — is when the most significant physiological restoration occurs:

• •Growth hormone release: Approximately 70% of daily GH secretion occurs during the first episode of slow-wave sleep
• •Cellular repair: Protein synthesis and tissue regeneration peak during SWS
• •Immune consolidation: Cytokine production and immune memory formation intensify during early sleep cycles
• •Memory consolidation: Declarative memories are transferred from hippocampus to neocortex during SWS

The regulatory systems controlling these processes involve multiple neuroendocrine pathways — the pineal gland, hypothalamic-pituitary axis, GABA-ergic systems, and cytokine networks. Research peptides offer a means to probe these pathways in controlled experimental settings.

The research interest in peptide-based sleep interventions stems from two distinct angles. First, many sleep disorders involve disrupted circadian regulation or blunted neuroendocrine responses — areas where targeted peptide signaling may offer mechanistic insights. Second, the interaction between sleep quality and overnight GH secretion makes GH-focused peptide research inherently relevant to sleep science.

---

Epithalon (Epitalon): Pineal Gland Peptide and Circadian Research

Overview

Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly, or AEDG) derived from Epithalamin, a polypeptide complex isolated from bovine pineal gland tissue. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, Epithalon represents one of the most extensively studied bioregulator peptides in the Khavinsonian research tradition.

The compound was confirmed present in physiological pineal gland extract in 2017, validating the hypothesis that AEDG represents a naturally occurring signaling peptide rather than a processing artifact of Epithalamin.

Mechanisms in Circadian and Sleep Research

Melatonin rhythm normalization: A landmark study by Korkushko et al. (PMID: 17969590) administered Epithalon to aged monkeys and elderly humans and documented normalization of blunted nocturnal melatonin surges characteristic of aging. In subjects with documented pineal gland functional insufficiency, both mean nightly melatonin levels and the amplitude of circadian melatonin rhythms increased following treatment. Melatonin is the primary endocrine signal encoding circadian phase information — its normalization has downstream effects on sleep onset timing, sleep architecture, and temperature regulation.

Telomerase activation: Khavinson's group demonstrated that Epithalon activates telomerase in somatic cell lines, producing measurable telomere elongation — a proposed cellular mechanism for its geroprotective properties. In the context of sleep research, this is relevant because telomere shortening is accelerated by chronic sleep deprivation.

Gene regulatory activity: Epithalon acts as a transcriptional bioregulator, modulating mRNA expression patterns in pineal and neuroendocrine cells — including genes involved in melatonin biosynthesis. A comprehensive 2025 review (PMID: 40141333) synthesized 25 years of Epithalon research across in vitro, in vivo, and in silico models, confirming significant geroprotective and neuroendocrine effects.

Research Role in a Sleep Protocol

In sleep-focused research protocols, Epithalon's primary relevance is as a circadian rhythm modulator operating at the pineal level — upstream of direct sleep-promoting compounds. By restoring melatonin secretion capacity in aged or chronically stressed subjects, it may provide a regulatory foundation that improves the consistency of sleep-dependent physiological processes without directly inducing sedation.

Researchers often study Epithalon as a baseline chronobiological support compound, examining whether circadian normalization improves the reliability of outcomes measured during sleep.

For further reading on this compound: Epitalon (AEDG Peptide): The Pineal Tetrapeptide in Telomerase and Aging Research

---

DSIP (Delta Sleep-Inducing Peptide): Delta-Wave Sleep Research

Overview

Delta Sleep-Inducing Peptide (DSIP) is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, first isolated from rabbit venous blood by Schoenenberger and colleagues in 1977. The name derives from early electrophysiological experiments showing that cerebral extracts containing this peptide induced increased delta-wave (slow-wave) activity in rabbit EEG recordings.

DSIP's identity as a neuropeptide is complicated by several unusual properties: it is found in peripheral tissues as well as the CNS, appears capable of crossing the blood-brain barrier, and has a multifunctional physiological profile that extends well beyond sleep modulation. Its endogenous receptor remains uncharacterized, and its mechanism of action is incompletely understood — making it one of the more scientifically intriguing research peptides.

Key Research Findings

Several human clinical investigations have examined DSIP's effects on sleep quality and architecture:

A 1981 study by Schneider-Helmert and Schoenenberger (PMID: 7028502) administered DSIP intravenously (25 nmol/kg) to six chronic insomniacs. Subjects showed longer sleep duration, higher subjective sleep quality, and marginally increased REM sleep relative to baseline. The sleep-promoting effects appeared approximately one to two hours after administration — consistent with a modulatory rather than sedative mechanism.

The foundational review by Graf and Kastin (PMID: 6145137), published in Neuroscience & Biobehavioral Reviews (1984), established the central research framework for DSIP. A key insight from this review: DSIP appears to normalize sleep-wake cycles rather than induce sedation per se, suggesting it operates by correcting dysregulated sleep mechanisms rather than overriding them pharmacologically.

A double-blind study in 14 middle-aged chronic insomniacs (PMID: 3622582) found that IV DSIP administered over seven successive nights improved sleep efficiency to levels approaching those of normal controls, with sustained improvements in daytime alertness and cognitive performance.

It is important to acknowledge that not all controlled studies found significant DSIP effects versus placebo. Some double-blind trials reported modest improvements that were not clearly distinguishable from placebo responses. The mixed evidence is consistent with DSIP's characterization as a sleep-modulating compound most likely to show effects in subjects with documented sleep architecture disruption.

Additional Research Dimensions

Beyond sleep, DSIP has been examined for:

• •Pain modulation (including a pilot study in chronic migraine and pain patients, PMID: 6548970)
• •Stress response and cortisol dynamics
• •Circadian neuroendocrine control

Research Considerations: Stability and Administration

DSIP has a reported plasma half-life of approximately 1–2 minutes when administered intravenously in native form, due to rapid enzymatic degradation. This pharmacokinetic profile presents significant methodological challenges for research design. Most human studies have used IV infusion to maintain plasma levels; intranasal administration has been explored as a route that may allow more direct CNS access and improved stability.

For a detailed profile of this compound: DSIP: The Enigmatic Nonapeptide in Sleep and Stress Research

---

Ipamorelin and GHRP-6: Overnight GH Pulse and Recovery Research

The GH-Sleep Connection

Growth hormone secretagogues occupy a central role in sleep and recovery research because of the fundamental relationship between sleep and GH secretion. In healthy adults, the largest single GH pulse of the day occurs during the first episode of slow-wave sleep — typically within 60–90 minutes of sleep onset. This nocturnal GH release drives protein synthesis, adipose tissue mobilization, tissue repair, and cellular regeneration.

Conversely, GH release itself appears to promote deeper sleep: subjects who receive GH-stimulating compounds often show increased slow-wave sleep duration on polysomnography, suggesting a bidirectional feedback relationship between nocturnal GH and sleep architecture.

Ipamorelin: The Selective GH Secretagogue

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) was characterized in a landmark 1998 paper by Raun et al. (PMID: 9849822) as "the first selective growth hormone secretagogue." The defining research finding: ipamorelin stimulates GH release through the ghrelin receptor (GHSR-1a) without significantly elevating ACTH or cortisol — even at doses more than 200-fold higher than its effective GH-releasing dose.

This selectivity is directly relevant to sleep research. Elevated cortisol during nighttime hours disrupts sleep architecture — it suppresses SWS, fragments sleep continuity, and attenuates the normal nocturnal GH pulse. A GH secretagogue that avoids cortisol elevation provides cleaner research conditions for studying overnight GH-dependent recovery without the confound of cortisol-mediated sleep disruption.

The research comparison: Ipamorelin vs GHRP-6: Research Comparison Guide covers the differential profiles of these two compounds in detail.

GHRP-6 as a Research Comparator

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) preceded ipamorelin chronologically and remains an important research standard. Its GH-releasing efficacy is well-established. Unlike ipamorelin, GHRP-6 does elevate prolactin, cortisol, and ACTH to a greater degree — making it a distinct research profile useful when researchers want to study broader pituitary activation alongside GH release.

In sleep stack protocols, ipamorelin's selectivity is generally preferred as it avoids the neuroendocrine confounds that complicate sleep architecture interpretation.

Research Protocol Considerations for GH Secretagogues in Sleep

Research designs investigating GH secretagogues in sleep contexts typically examine:

• •Whether pharmacologically enhanced GH pulsatility translates to measurable SWS architecture improvements
• •IGF-1 levels as a downstream marker of overnight GH activity
• •Inflammatory markers and recovery biomarkers as sleep quality surrogates
• •Timing optimization relative to the natural circadian GH secretion pattern (pre-sleep administration is most studied)

For further reading: Ipamorelin: The Selective Growth Hormone Secretagogue — Complete Research Profile

---

Selank: Anxiolytic Properties and Sleep Quality Research

Overview

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide analog of tuftsin, an endogenous immunomodulatory tetrapeptide. Developed at the Institute of Molecular Genetics in Moscow, Selank is registered as an anxiolytic peptide drug in Russia and has been studied extensively across preclinical and limited clinical settings.

The Pro-Gly-Pro extension added to the tuftsin core (Thr-Lys-Pro-Arg) significantly enhances enzymatic stability, allowing Selank to maintain activity in biological fluids substantially longer than the parent peptide.

Anxiolytic Mechanisms Relevant to Sleep Architecture

Anxiety and hyperarousal are among the most common and best-characterized factors disrupting both sleep onset and sleep maintenance. Research into Selank's anxiolytic mechanisms has identified several pharmacological pathways:

GABAergic modulation: Selank enhances GABAergic neurotransmission through allosteric mechanisms, without direct benzodiazepine receptor binding. This distinguishes its mechanism from benzodiazepines, which carry tolerance, dependence, and REM-suppression concerns in research models.

Serotonin turnover: Increased serotonin metabolism in key brain regions — hippocampus, frontal cortex, and hypothalamus — has been observed in preclinical Selank studies. Serotonin is the direct precursor to melatonin and plays a modulatory role in sleep architecture, particularly REM sleep.

BDNF regulation: Selank modulates BDNF (brain-derived neurotrophic factor) expression. BDNF plays roles in hippocampal plasticity, stress response, and sleep-dependent memory consolidation processes.

Selank and Immune-Sleep Axis Research

This dual anxiolytic-immunomodulatory profile distinguishes Selank from pure sedative compounds in sleep research contexts. Rather than inducing sleep through CNS depression, the research hypothesis is that Selank may improve sleep quality by reducing the anxious hyperarousal and neuroimmune signaling patterns that prevent normal sleep onset and architecture.

Differentiation from Cognitive Stack Dosing

Selank also appears in cognitive enhancement research protocols (see: Cognitive Peptide Research Stack 2026: Semax + Selank + Dihexa). In that context, Selank is studied for anxiolytic-nootropic effects during active waking hours.

In a sleep-focused protocol, the administration timing and research rationale differ: Selank is administered in the pre-sleep window, leveraging its anxiolytic properties to facilitate sleep onset, rather than during daytime hours where its cognitive-supportive effects are primary.

---

Research Stack Protocol Design

Researchers studying combinations of sleep-modulating peptides typically structure investigations around four design principles.

Mechanistic Complementarity

The four compounds described represent distinct mechanistic levels in sleep regulation:

Protocol Timing Considerations

In animal model research, compound timing relative to the dark phase onset is carefully controlled. Melatonin-modulating compounds (Epithalon) are studied in relation to circadian phase. Direct sleep-promoting peptides (DSIP) are studied relative to anticipated sleep onset. GH secretagogues are studied for timing relative to the first anticipated SWS episode.

Measurement Endpoints

Sleep research protocols using peptide compounds require polysomnographic (PSG) monitoring to assess:

• •Sleep efficiency (time asleep / time in bed)
• •SWS duration and proportion
• •REM cycle frequency and LATENCY
• •Sleep onset latency

Paired endocrine measurements (IGF-1, cortisol, melatonin, GH AUC) provide hormonal correlates to confirm whether peptide-mediated endocrine changes track with architectural improvements.

Sequential Compound Characterization

Sound research methodology characterizes individual compounds before studying combinations. Before designing a four-compound sleep stack protocol, researchers establish each compound's individual effect profile, administration timing, dose-response relationship, and potential for pharmacokinetic or pharmacodynamic interactions in separate experimental arms.

---

Additional Research Resources

• •Epitalon Dosage Protocol Guide — Reconstitution, Research Cycles & Telomerase Research
• •DSIP Dosage Protocol Guide — Reconstitution, Research Dosing & Sleep Research
• •Ipamorelin Dosage Protocol Guide 2026
• •Selank Dosage Protocol Guide: Intranasal Research
• •Peptide Stack Builder & Comparison Tool

---

Research Limitations and Considerations

Bioavailability variability: Sleep-relevant peptides show route-dependent bioavailability profiles that differ substantially. DSIP has a plasma half-life of approximately 1–2 minutes IV, while Epithalon and Selank show longer activity via subcutaneous and intranasal routes respectively. Research designs must account for these pharmacokinetic differences when interpreting timing effects.

Individual response variation: Sleep architecture is highly individual, influenced by genetic variants in circadian clock genes (CLOCK, BMAL1, PER genes), baseline melatonin production, GH secretion patterns, and stress physiology. This biological variation makes controlled research designs with sufficient sample sizes essential.

Combination interaction research: Studying combinations of neuroendocrine-active peptides requires careful design to distinguish additive from synergistic or potentially antagonistic effects. Most published research characterizes individual compounds; formal combination studies are limited.

Regulatory status: None of the compounds described — Epithalon, DSIP, Ipamorelin, GHRP-6, or Selank — are approved by the FDA for human use. All are available for research purposes only.

---

References

1. Korkushko OV, Khavinson VK, Shatilo VB, Antonyk-Sheglova IA. Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people. Adv Gerontol. 2007;20(1):74–85. PMID: 17969590

2. Khavinson VK, Linkova NS, Kozhevnikova EO. Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci. 2025. PMID: 40141333

3. Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP (delta-sleep-inducing peptide) on disturbed human sleep. Experientia. 1981;37(9):913–7. PMID: 7028502

4. Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984;8(1):83–93. PMID: 6145137

5. Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Neuropsychobiology. 1987;17(4):171–5. PMID: 3622582

6. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–61. PMID: 9849822